Dosage regimen of vidofludimus for use in the treatment of chronic inflammatory and / or autoimmune diseases

Abstract

The present invention relates to 2-({3-fluoro-3'-methoxy-[1,1'-biphenyl]-4-yl}carbamoyl)cyclopent-1-ene-1-carboxylic acid) according to formula (I) and to a novel dosage regimen, as well as to their uses in the treatment of chronic inflammatory and / or autoimmune diseases. The compound of formula (I) mentioned inhibits dihydroorotate dehydrogenase (DHODH) and is known for the treatment and prevention of diseases, in particular its use in diseases in which there is an advantage in inhibiting dihydroorotate dehydrogenase (DHODH).